Jessica C Cardenas1,2, Charles E Wade1,2, Bryan A Cotton1,2, Mitchell J George1, John B Holcomb1,2, Martin A Schreiber3, Nathan J White4. 1. Division of Acute Care Surgery, Department of Surgery, The University of Texas Health Science Center and the McGovern School of Medicine, Houston, Texas. 2. Center for Translational Injury Research, Houston, Texas. 3. Division of Trauma, Critical Care, and Acute Care Surgery, Oregon Health and Science University, Portland, Oregon. 4. The University of Washington Department of Emergency Medicine, Harborview Medical Center, Seattle, Washington.
Abstract
BACKGROUND:Thrombelastography (TEG) fibrinolysis shutdown after trauma is associated with increased mortality due to hypercoagulability-associated organ failure. However, a lack of mechanistic data has precluded the development of novel interventions to treat shutdown. OBJECTIVES: To define the pathophysiology of TEG shutdown in severely injured, bleeding patients through secondary analysis of the PROPPR trial. METHODS:Fibrinolysis was characterized in PROPPR subjects using admission TEG lysis at 30 min (LY30) or plasmin-antiplasmin (PAP) levels. LY30 categories were low (<0.9%), moderate (0.9-2.9%), or high (≥ 3%). PAP was classified as low (<1,500 μg/L), moderate (1,500-20,000 μg/L), or high (>20,000 μg/L). Demographics, outcomes, admission TEG values, platelet count and function, standard coagulation tests, and coagulation proteins were compared. RESULTS:Five hundred forty-seven patients had TEG data and 549 patients had PAP data available. Low LY30 was associated with reduced platelet count and aggregation, poorer TEG clot formation, prolonged clotting times, and reduced fibrinogen and alpha2 antiplasmin. Compared to moderate PAP, low PAP subjects had similar platelet parameters, TEG values, fibrinogen, and alpha2 antiplasmin, but reduced tPA, and elevated PAI-1. D-Dimer values increased as PAP increased, however patients with low LY30 had elevated D-Dimer compared with moderate LY30 patients. Most low LY30 deaths were due to TBI (45%) and hemorrhage (42%) versus one of each cause (TBI, hemorrhage, MOF) in low PAP patients. CONCLUSIONS: Low TEG LY30 does not reflect shutdown of enzymatic fibrinolysis with hypercoagulability, but rather a coagulopathic state of moderate fibrinolysis with fibrinogen consumption and platelet dysfunction that is associated with poor outcomes.
RCT Entities:
BACKGROUND: Thrombelastography (TEG) fibrinolysis shutdown after trauma is associated with increased mortality due to hypercoagulability-associated organ failure. However, a lack of mechanistic data has precluded the development of novel interventions to treat shutdown. OBJECTIVES: To define the pathophysiology of TEG shutdown in severely injured, bleedingpatients through secondary analysis of the PROPPR trial. METHODS: Fibrinolysis was characterized in PROPPR subjects using admission TEG lysis at 30 min (LY30) or plasmin-antiplasmin (PAP) levels. LY30 categories were low (<0.9%), moderate (0.9-2.9%), or high (≥ 3%). PAP was classified as low (<1,500 μg/L), moderate (1,500-20,000 μg/L), or high (>20,000 μg/L). Demographics, outcomes, admission TEG values, platelet count and function, standard coagulation tests, and coagulation proteins were compared. RESULTS: Five hundred forty-seven patients had TEG data and 549 patients had PAP data available. Low LY30 was associated with reduced platelet count and aggregation, poorer TEG clot formation, prolonged clotting times, and reduced fibrinogen and alpha2 antiplasmin. Compared to moderate PAP, low PAP subjects had similar platelet parameters, TEG values, fibrinogen, and alpha2 antiplasmin, but reduced tPA, and elevated PAI-1. D-Dimer values increased as PAP increased, however patients with low LY30 had elevated D-Dimer compared with moderate LY30patients. Most low LY30deaths were due to TBI (45%) and hemorrhage (42%) versus one of each cause (TBI, hemorrhage, MOF) in low PAP patients. CONCLUSIONS: Low TEG LY30 does not reflect shutdown of enzymatic fibrinolysis with hypercoagulability, but rather a coagulopathic state of moderate fibrinolysis with fibrinogen consumption and platelet dysfunction that is associated with poor outcomes.
Authors: Hunter B Moore; Ernest E Moore; Ioannis N Liras; Eduardo Gonzalez; John A Harvin; John B Holcomb; Angela Sauaia; Bryan A Cotton Journal: J Am Coll Surg Date: 2016-01-22 Impact factor: 6.113
Authors: John R Taylor; Erin E Fox; John B Holcomb; Sandro Rizoli; Kenji Inaba; Martin A Schreiber; Karen Brasel; Thomas M Scalea; Charles E Wade; Eileen Bulger; Bryan A Cotton Journal: J Trauma Acute Care Surg Date: 2018-01 Impact factor: 3.313
Authors: Jonathan P Meizoso; Charles A Karcutskie; Juliet J Ray; Nicholas Namias; Carl I Schulman; Kenneth G Proctor Journal: J Am Coll Surg Date: 2016-12-23 Impact factor: 6.113
Authors: Sarah Baraniuk; Barbara C Tilley; Deborah J del Junco; Erin E Fox; Gerald van Belle; Charles E Wade; Jeanette M Podbielski; Angela M Beeler; John R Hess; Eileen M Bulger; Martin A Schreiber; Kenji Inaba; Timothy C Fabian; Jeffrey D Kerby; Mitchell Jay Cohen; Christopher N Miller; Sandro Rizoli; Thomas M Scalea; Terence O'Keeffe; Karen J Brasel; Bryan A Cotton; Peter Muskat; John B Holcomb Journal: Injury Date: 2014-06-10 Impact factor: 2.586
Authors: H B Moore; E E Moore; M P Chapman; E Gonzalez; A L Slaughter; A P Morton; A D'Alessandro; K C Hansen; A Sauaia; A Banerjee; C C Silliman Journal: J Thromb Haemost Date: 2015-09-22 Impact factor: 5.824
Authors: Hunter B Moore; Ernest E Moore; Eduardo Gonzalez; Michael P Chapman; Theresa L Chin; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: J Trauma Acute Care Surg Date: 2014-12 Impact factor: 3.313
Authors: Jessica C Cardenas; Nena Matijevic; Lisa A Baer; John B Holcomb; Bryan A Cotton; Charles E Wade Journal: Shock Date: 2014-06 Impact factor: 3.454
Authors: Michael P Chapman; Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Fabia Gamboni; James G Chandler; Sanchayita Mitra; Arsen Ghasabyan; Theresa L Chin; Angela Sauaia; Anirban Banerjee; Christopher C Silliman Journal: J Trauma Acute Care Surg Date: 2016-01 Impact factor: 3.313
Authors: Hunter B Moore; Ernest E Moore; Matthew D Neal; Forest R Sheppard; Lucy Z Kornblith; Dominik F Draxler; Mark Walsh; Robert L Medcalf; Mitch J Cohen; Bryan A Cotton; Scott G Thomas; Christine M Leeper; Barbara A Gaines; Angela Sauaia Journal: Anesth Analg Date: 2019-09 Impact factor: 5.108
Authors: Hunter B Moore; Ernest E Moore; Michael P Chapman; Kirk C Hansen; Mitchell J Cohen; Frederic M Pieracci; James Chandler; Angela Sauaia Journal: J Am Coll Surg Date: 2019-03-29 Impact factor: 6.113
Authors: Hunter B Moore; Matthew D Neal; Marnie Bertolet; Brian A Joughin; Michael B Yaffe; Christopher D Barrett; Molly A Bird; Russell P Tracy; Ernest E Moore; Jason L Sperry; Brian S Zuckerbraun; Myung S Park; Mitchell J Cohen; Stephen R Wisniewski; James H Morrissey Journal: Ann Surg Open Date: 2022-05-25
Authors: Robert P Richter; Danielle M Joiner; Russell L Griffin; Jan O Jansen; Jeffrey D Kerby; Charles E Wade; John B Holcomb; Jessica C Cardenas; Jillian R Richter Journal: Ann Surg Open Date: 2022-03
Authors: Nathan Dow; Julia R Coleman; Hunter Moore; Zachary T Osborn; Adrian M Sackheim; Grant Hennig; Saulius Butenas; Mark T Nelson; Ernest E Moore; Kalev Freeman Journal: J Trauma Acute Care Surg Date: 2020-02 Impact factor: 3.697
Authors: Ernest E Moore; Hunter B Moore; Lucy Z Kornblith; Matthew D Neal; Maureane Hoffman; Nicola J Mutch; Herbert Schöchl; Beverley J Hunt; Angela Sauaia Journal: Nat Rev Dis Primers Date: 2021-04-29 Impact factor: 65.038